Gary D. Glick

[Odyssey Therapeutics @Odyssey_Tx]

Today, Odyssey Therapeutics announced the closing of an oversubscribed $218 million Series A financing to advance our next generation precision immunomodulators and oncology medicines. Read more:
https://t.co/Q2ePCiRbzq
#biotech #drugdiscovery #odyssey

[IFM Therapeutics @IFMThera]

Why do we do what we do? At IFM, our goal is to discover & develop innovative drug candidates that address unmet needs for patients with #inflammatory diseases, #autoimmune disorders and #cancer. Learn more: https://t.co/seKYbo0q8f #innateimmune

[IFM Therapeutics @IFMThera]

#DYK #Innateimmune PRRs (Pattern Recognition Receptors) are the body's 1st line of defense against pathogens but, when dysregulated, can drive inflammatory disease? IFM works to develop therapies that target these PRRs with the goal of treating serious #autoinflammatory diseases.

[IFM Therapeutics @IFMThera]

Aicardi-Goutières syndrome (AGS) is a serious, rare genetic disorder affecting children, in which activation of the #cGAS/STING pathway is believed to play a key role. Learn how we're inhibiting cGAS/STING via our subsidiary, IFM Due: #innateimmmunity #AGS

[IFM Therapeutics @IFMThera]

Curious to know how innate immunity works? Our dedicated team of scientists tap into the potential of #innateimmunity to develop next generation therapies. Learn more about the team:

[IFM Therapeutics @IFMThera]

Neurodegenerative diseases such as #Parkinsons and #ALS are associated with activation of predominantly #innateimmune pathways like the cGAS/STING. See how we're working to develop therapies that target the innate immune system and treat diseases with a neuroinflammatory driver:

[Drug Target Review @DrugTargetRev]

Researchers at @AgenciaFAPESP have shown that the presence of the #inflammasome mediated by NLRP3 is a marker and drug target for #COVID19 related #cytokine storms.
Click here: https://t.co/CLY2Hq3kMP

[IFM Therapeutics @IFMThera]

This #Thanksgiving may look different, but what remains the same is our genuine appreciation for our team. We're so grateful for their hard work, passion and drive to save lives ! #Thankful #HappyThanksgiving

[IFM Therapeutics @IFMThera]

It’s Science Spotlight time! Read our picks for top research studies in #innateimmunity and #inflammation from the past month:

[IFM Therapeutics @IFMThera]

Congrats to the @sloan_kettering team on its research on neuroinflammation & Alzheimer’s disease. For more on the link between the innate immune system & neurodegenerative diseases, read about our scientific advisor Dr. Michael Heneka’s work in this area: https://t.co/MYWxoR2YOF

[IFM Therapeutics @IFMThera]

What's our promise to help address significant unmet needs in #immunotherapies? Our small-molecule inhibitors selectively reduce inappropriate #immune responses and stop the body from attacking itself. Learn more:

[IFM Therapeutics @IFMThera]

We’re extremely proud of our IFM Due co-founder Andrea Ablasser, MD and her colleagues @EPFL_ReO for their recently published work on BAF’s role in fighting off viral infections. Read more: @ScienceMagazine

[IFM Therapeutics @IFMThera]

Via our IFM Discovery incubator, we focus on genetically-validated pattern recognition receptor targets with potential implications in more than a dozen serious diseases. Learn how we're curbing #immune responses to better treat inflammatory diseases:

[IFM Therapeutics @IFMThera]

At IFM, our goal is to create drug candidates that solve the most challenging problems in the treatment of inflammatory diseases, autoimmune disorders and cancers. The question that motivates us is, "How will my work help to improve the lives of patients with these conditions?"

[IFM Therapeutics @IFMThera]

Nucleic acid signaling pathways of the #innateimmune system, such as cGAS/STING, MDA5 & RIG-1, can drive severe #autoimmune & #autoinflammatory diseases. Learn about these pathways and their therapeutic potential in @NatImmunol from our IFM Due co-founder, Dr. Andrea Ablasser:

[IFM Therapeutics @IFMThera]

Pattern Recognition Receptors (PRRs) are a key element of the innate #immune system that help detect threats and direct the body to mount an inflammatory response. IFM has developed a platform approach to target several PRRs—read about them in @britsocimm: https://t.co/3J5V82UHAQ

[Biomedical Journal @BiomedJ]

Innate Immunity Drives Pathogenesis of Rheumatoid Arthritis.

Monocytes, macrophages, dendritic cells, neutrophils, natural killer cells & innate lymphoid cells play a key role in the early stages & progression of rheumatoid #arthritis.

https://t.co/frqqhjLCb8 #immunology #RA

[IFM Therapeutics @IFMThera]

#Happy4thofJuly from all of us at IFM Therapeutics! Normally we’d be watching fireworks from our office in #Boston’s Back Bay, but this year we’re keeping safe at home and celebrating with our families. We hope you are, as well!

[IFM Therapeutics @IFMThera]

Our IFM Discovery incubator is evaluating numerous genetically-validated innate immune targets that are amenable to precision medicine approaches. Why did we establish this incubator? Find out in @fiercebiotech: https://t.co/5RDYqgVP4m

[IFM Therapeutics @IFMThera]

The innate immune system is the body's first line of defense, but most recent immunotherapies have focused on the adaptive immune system. Learn why we think the next big breakthrough will be in #innateimmunity.